- Home
- TALO vs CNTA Comparison
TALO vs CNTA Comparison
Compare TALO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | CNTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 6.1B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TALO | CNTA |
|---|---|---|
| Price | $15.36 | $39.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $18.00 | ★ $43.17 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,780,070,000.00 | $15,000,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.67 | $10.95 |
| 52 Week High | $17.01 | $40.26 |
Technical Indicators
Market Signals| Indicator | TALO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 72.11 |
| Support Level | $10.49 | $39.36 |
| Resistance Level | $16.28 | $39.86 |
| Average True Range (ATR) | 0.55 | 0.15 |
| MACD | -0.05 | -0.39 |
| Stochastic Oscillator | 50.91 | 47.52 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.